Phase III results show antiviral treatment favipiravir demonstrated a 28.6% faster viral clearance of Covid-19 compared to placebo. – Glenmark Pharma
Glenmark announced Phase III results that showed its antiviral treatment favipiravir demonstrated a 28.6% faster viral clearance of COVID-19 compared to placebo . Favipiravir is a broad-spectrum oral… read more.